Subbarayan Pochi R, Ardalan Bach
Department of Medicine, University of Miami Miller School of Medicine, 1550 NW 10th Avenue, FOX 431A, Miami, FL, 33136, USA.
J Gastrointest Cancer. 2014 Sep;45(3):363-71. doi: 10.1007/s12029-014-9617-8.
In the past decade, the therapeutic potential of arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) was recognized. This encouraged other investigators to test the efficacy of ATO in the management of other hematological and solid tumor malignancies. Notably, as a single agent, arsenic trioxide did not benefit patients diagnosed with solid tumors. However, when it was combined with other agents, treatment benefit emerged. In this article, we have summarized the outcome of clinical trials that used arsenic trioxide as a single agent as well as in combination settings in patients diagnosed with solid tumors. We have also reviewed possible additional mechanisms by which ATO may be useful as a chemosensitizer in combination therapy. We hope that our review will encourage clinical investigators to rationally combine ATO with additional chemotherapeutic agents in treating patients diagnosed with solid tumors.
在过去十年中，三氧化二砷（ATO）治疗急性早幼粒细胞白血病（APL）的治疗潜力得到了认可。这促使其他研究人员测试ATO在治疗其他血液系统和实体瘤恶性肿瘤中的疗效。值得注意的是，作为单一药物，三氧化二砷对诊断为实体瘤的患者并无益处。然而，当它与其他药物联合使用时，治疗效果显现出来。在本文中，我们总结了将三氧化二砷作为单一药物以及在联合治疗中用于诊断为实体瘤患者的临床试验结果。我们还回顾了ATO作为联合治疗中的化学增敏剂可能发挥作用的其他潜在机制。我们希望我们的综述将鼓励临床研究人员在治疗诊断为实体瘤的患者时合理地将ATO与其他化疗药物联合使用。
